enfortumab vedotin (Padcev) Report issue

Biologics mAb ADC Approved FDA Accelerated Approval FDA
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1611.6600 - $3149.1000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ags-22ce | ags-22m6e | ags-22me | asg-22ce | asg-22me | enfortumab vedotin

Organizations (28)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (1)


 

Carcinoma, Transitional Cell (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Adenocarcinoma (Phase 2)

Carcinoma in Situ (Phase 1)

Carcinoma, Transitional Cell (Phase 3)

Medical Oncology (Phase 1)

Neoplasms (Phase 2/Phase 3)

Pancreatic Neoplasms (Phase 2)

Penile Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Ureteral Neoplasms (Phase 3)

Urethral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Urologic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 32
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue